598 completed, 73 terminated, 34 unknown, 19 withdrawn. 165 Phase 3, 158 Phase 4, 146 Phase 2, 85 Not applicable, 54 Phase 1.
Follow Allergan: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment JUVÉDERM, BOTOX, HArmonyCA Lidocaine - Facial Rhytides, Skin Folds | Phase 4 | Completed | Allergan | 64 | 2023-02-15 | 2025-06-17 |
| Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV Cenicriviroc Mesylate (CVC), Placebo - HIV Infections | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-11-22 | 2022-12-21 | |
| A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants HArmonyCa Lidocaine Injectable Gel - Mid Face Volume Deficit | Phase 3 | Completed | Allergan | 171 | 2022-09-02 | 2026-06-01 |
| Investigation of Eluxadoline for Diabetic Diarrhea Eluxadoline 100 mg - Diabetic Diarrhea, Diabetes | Phase 2 / Phase 3 | Withdrawn | Temple University | 2022-07-01 | 2023-05-06 | |
| Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia AGN-190584, Vehicle - Presbyopia | Phase 2 | Withdrawn | Allergan | 2022-06-09 | 2022-06-29 | |
| Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence onabotulinumtoxin A - Stress Urinary Incontinence | Early Phase 1 | Suspended | Northwell Health | 20 | 2022-02-14 | 2026-01-26 |
| A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines OnabotulinumtoxinA X, Placebo - Forehead Lines | Phase 2 | Completed | Allergan | 124 | 2021-11-29 | 2025-07-16 |
| XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma XEN45 gel stent implantation - Glaucoma, Glaucoma, Open-Angle | Not applicable | Unknown | Zhongshan Ophthalmic Center, Sun Yat-sen University | 20 | 2021-11-07 | 2021-11-23 |
| Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines OnabotulinumtoxinA - Glabellar Frown Lines | Early Phase 1 | Unknown | Clinical Testing of Beverly Hills | 40 | 2021-10-20 | 2021-10-27 |
| Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbital Hollowing in Chinese Adult Participants VOLBELLA with Lidocaine - Infraorbital Hollowing | Phase 3 | Completed | Allergan | 160 | 2021-10-19 | 2024-11-25 |
| HArmonyCa Injectable Gel for Mid Face Soft Tissue Augmentation HArmonyCa Injectable Gel - Soft Tissue Augmentation | Phase 4 | Completed | Allergan | 140 | 2021-10-13 | 2024-09-19 |
| A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines OnabotulinumtoxinA X, Placebo - Glabellar Lines | Phase 2 | Completed | Allergan | 328 | 2021-10-06 | 2025-09-09 |
| VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatment for FORehead Contouring and Marionette Lines Juvéderm® VOLIFT™ with Lidocaine - Marionette Lines Forehead Contouring | Phase 4 | Completed | Allergan | 163 | 2021-09-15 | 2022-11-30 |
| A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily Pilocarpine HCl, Vehicle - Presbyopia | Phase 3 | Completed | Allergan | 230 | 2021-09-02 | 2023-03-21 |
| A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA - Glabellar Lines | Phase 2 | Completed | Allergan | 92 | 2021-09-01 | 2025-06-27 |
| Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine Atogepant - Chronic Migraine | Phase 3 | Completed | Allergan | 3 | 2021-08-02 | 2023-05-24 |
| JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population JUVÉDERM® VOLUMA® with Lidocaine - Temple Hollowing | Phase 3 | Completed | Allergan | 168 | 2021-07-20 | 2024-12-12 |
| Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device Restasis - Ocular Surface Disease | Phase 1 / Phase 2 | Completed | Boston Sight | 10 | 2021-07-15 | 2025-01-13 |
| Botulinum Toxin Type A for Cold Intolerance Secondary to Digital Amputations and Replantations: A Pilot Study Botulinum toxin type A - Cold Intolerance | Phase 1 | Unknown | Massachusetts General Hospital | 28 | 2021-06-02 | 2022-08-24 |
| CoolSculpting® Elite for Non-Invasive Fat Reduction CoolSculpting® Elite System with CoolSculpting® Elite applicators - Non-invasive Fat Reduction | Phase 4 | Completed | Allergan | 110 | 2021-05-18 | 2023-10-05 |
Showing 20 of 728. Sign in to see all of them.
Ocular Hypertension (80) · Dry Eye Syndromes (63) · Glaucoma, Open-Angle (56) · Glaucoma (43) · Macular Edema (35) · Migraine Disorders (31) · Muscle Spasticity (29) · Urinary Bladder, Overactive (27) · Retinal Vein Occlusion (20) · Acne Vulgaris (19) · Urinary Incontinence (17) · Macular Degeneration (15) · Stroke (15) · Diabetes Mellitus (13) · Conjunctivitis, Allergic (11)
Botulinum Toxins, Type A (165) · Bimatoprost (58) · Dexamethasone (49) · Calcium Dobesilate (43) · Saline Solution (40) · Ophthalmic Solutions (27) · Brimonidine Tartrate (25) · Sodium Chloride (22) · salicylhydroxamic acid (20) · Ranibizumab (19) · Timolol (19) · Cyclosporins (14) · Brimonidine Tartrate, Timolol Maleate Drug Combination (13) · Lubricant Eye Drops (13) · Latanoprost (12)
United States (477) · Canada (114) · Germany (75) · United Kingdom (73) · France (60) · Australia (51) · South Korea (41) · Poland (40) · Spain (37) · Italy (35) · Czechia (33) · Belgium (28) · China (27) · Russia (26) · Israel (24)
Joel Trugman, MD (4) · Adele Thorpe (3) · Ahunna Ukah (3) · Andrew Schumacher (3) · Anna Chan (3) · Curtis Nickel, MD (3) · David Charles, M.D. (3) · Eleonora Safyan (3) · Elizabeth Makino (3) · Esther Jo (3) · Joan-En Lin (3)
PMID 39982105, PMID 39648629, PMID 33142014, PMID 33206392, PMID 33942560, PMID 38462625, PMID 21571677, PMID 34874514, PMID 35643967, PMID 39648617, PMID 39715475, PMID 19476406, PMID 19855289, PMID 20008710, PMID 20384750, PMID 20427088, PMID 20487038, PMID 21145532, PMID 21883197, PMID 22999634, PMID 24754838, PMID 25080874, PMID 25260889, PMID 25288099, PMID 25439614, PMID 25500317, PMID 26231052, PMID 26519345, PMID 26581718, PMID 26802783, PMID 27847545, PMID 30293228, PMID 30500139, PMID 30500140, PMID 30500141, PMID 30969201, PMID 31112399, PMID 31444600, PMID 31654188, PMID 32134802, PMID 32665528, PMID 33026630, PMID 33026631, PMID 33241721, PMID 33608814, PMID 33874756, PMID 33955921, PMID 34288094, PMID 35468729, PMID 36125279
2014 (9), 2017 (7), 2018 (3), 2019 (3), U10EY014229 (3), U10EY014231 (3), U10EY018817 (3), 2015 (2), 2004 (1), 2009 (1), R01EY031315 (1), U10EY014351 (1), U10EY014352 (1), U10EY014404 (1), U54NS065701 (1)